Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Accumulated Depreciation & Amortization: 2019-2023

Historic Accumulated Depreciation & Amortization for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$5.3 million.

  • ADC Therapeutics' Accumulated Depreciation & Amortization fell 423983.00% to -$5.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$11.7 million, marking a year-over-year decrease of 188.36%. This contributed to the annual value of $344,000 for FY2022, which is 166.67% up from last year.
  • ADC Therapeutics' Accumulated Depreciation & Amortization amounted to -$5.3 million in Q3 2023, which was up 2.58% from -$5.4 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Accumulated Depreciation & Amortization peaked at $3.4 million during Q4 2022, and registered a low of -$5.4 million during Q2 2023.
  • Over the past 3 years, ADC Therapeutics' median Accumulated Depreciation & Amortization value was -$1,956 (recorded in 2021), while the average stood at -$1.4 million.
  • As far as peak fluctuations go, ADC Therapeutics' Accumulated Depreciation & Amortization surged by 183.75% in 2022, and later crashed by 915,205.31% in 2023.
  • ADC Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at -$3.0 million in 2019, then crashed by 102.75% to -$1,107 in 2020, then tumbled by 224.39% to -$4.1 million in 2021, then soared by 183.75% to $3.4 million in 2022, then tumbled by 423,983.00% to -$5.3 million in 2023.
  • Its Accumulated Depreciation & Amortization was -$5.3 million in Q3 2023, compared to -$5.4 million in Q2 2023 and -$4.5 million in Q1 2023.